Xarelto Lawsuit Update: Internal Bleeding Lawsuit Filed in New York

September 16, 2015 – – BloodThinnerHelp.com reports today on one of the latest Xarelto lawsuit filings. Recently, a Texas woman filed a lawsuit against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson, in the Eastern District of New York. She is alleging that the manufacturer’s failure to adequately warn doctors and patients about the real risks of Xarelto and their failure to perform sufficient safety tests on the drug led to her serious internal bleeding injuries. The full complaint can be found here and is filed under the federal court docket number 1:14-CV-04524.

In this case, the plaintiff was prescribed Xarelto by her doctor and began taking it to prevent blood clots that may be caused by atrial fibrillation, a heart condition. She was using Xarelto for five months when she experienced a severe internal bleeding event that left her seriously injured. The complaint does not specify the injuries sustained but it does note that the injuries she suffered are permanent and will require long term future care.

Xarelto was approved by the Food and Drug Administration, FDA, for released onto the United States market in 2011. Xarelto’s manufacturers pushed the drug as a convenient alternative to the traditional blood thinner Warfarin because of Xarelto’s ‘one size fits all’ dosage and lack of required blood monitoring. Advertisements for the drug were heavily published in medical journals and television commercials for the drug featured well known athletes and public figures. Xarelto was initially approved for usage in patients who suffered from atrial fibrillation, deep vein thrombosis, or who have recently undergone knee or hip replacement surgeries.

The problem with Xarelto is that there is no antidote to the anticoagulant effects of the drug which makes it especially dangerous. If a patient is taking Warfarin and experiences an internal bleeding emergency, a doctor can administer vitamin K to reverse the effects of the Warfarin and the blood will clot. If a patient is taking Xarelto and experiences an internal bleeding emergency, there is no way to stop the bleeding. Xarelto currently has two ‘black box’ warnings attached to it by the FDA. The black box warning is the most strict warning the FDA can assign to a drug short of recalling it.

“If the manufacturers of Xarelto did conceal information about the true dangers of the drug, they deserve to be brought to justice,” Xarelto attorney Marc Goldich said. “If you or a loved one feel that you have been harmed by Xarelto, contact us immediately.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60004201